Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Cash (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Change in Cash for 13 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 106.5% year-over-year to -$1.3 million, compared with a TTM value of $21.4 million through Dec 2025, up 106.44%, and an annual FY2025 reading of $21.4 million, up 106.44% over the prior year.
  • Change in Cash was -$1.3 million for Q4 2025 at Tandem Diabetes Care, down from $27.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $48.7 million in Q4 2022 and bottomed at -$51.1 million in Q3 2023.
  • Average Change in Cash over 5 years is -$198950.0, with a median of $2.2 million recorded in 2023.
  • Peak annual rise in Change in Cash hit 1974.14% in 2025, while the deepest fall reached 14208.11% in 2025.
  • Year by year, Change in Cash stood at -$41.2 million in 2021, then soared by 218.3% to $48.7 million in 2022, then crashed by 142.57% to -$20.7 million in 2023, then surged by 197.36% to $20.2 million in 2024, then plummeted by 106.5% to -$1.3 million in 2025.
  • Business Quant data shows Change in Cash for TNDM at -$1.3 million in Q4 2025, $27.8 million in Q3 2025, and $10.5 million in Q2 2025.